Comment from Ansuman Satpathy

Summary: Dr. Ansuman Satpathy, a physician-scientist and biotechnology entrepreneur, supports the proposed Expedited Investigational New Drug (IND) Pilot Program. He recommends specific structural improvements, such as allowing QRI consortia, and suggests a future phase where proven QRIs could be granted greater decision-making authority to further accelerate drug development.